Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer is likely to show GSK significant competition
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Construction will begin this year with the new capacity anticipated by 2025
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
